NYSE - Nasdaq Real Time Price USD

Eli Lilly and Company (LLY)

Compare
955.38 +5.41 (+0.57%)
As of 2:32 PM EDT. Market Open.
Loading Chart for LLY
DELL
  • Previous Close 949.97
  • Open 955.61
  • Bid 953.38 x 1200
  • Ask 954.19 x 1100
  • Day's Range 939.17 - 956.50
  • 52 Week Range 516.57 - 967.00
  • Volume 1,771,486
  • Avg. Volume 3,242,212
  • Market Cap (intraday) 860.244B
  • Beta (5Y Monthly) 0.41
  • PE Ratio (TTM) 118.39
  • EPS (TTM) 8.07
  • Earnings Date Oct 30, 2024
  • Forward Dividend & Yield 5.20 (0.55%)
  • Ex-Dividend Date Aug 15, 2024
  • 1y Target Est 1,002.59

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

www.lilly.com

43,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: LLY

View More

Performance Overview: LLY

Trailing total returns as of 8/21/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

LLY
64.69%
S&P 500
17.99%

1-Year Return

LLY
76.01%
S&P 500
28.79%

3-Year Return

LLY
263.93%
S&P 500
26.71%

5-Year Return

LLY
821.98%
S&P 500
94.03%

Compare To: LLY

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: LLY

View More

Valuation Measures

Annual
As of 8/20/2024
  • Market Cap

    855.38B

  • Enterprise Value

    880.91B

  • Trailing P/E

    116.99

  • Forward P/E

    58.82

  • PEG Ratio (5yr expected)

    1.25

  • Price/Sales (ttm)

    22.06

  • Price/Book (mrq)

    63.07

  • Enterprise Value/Revenue

    22.63

  • Enterprise Value/EBITDA

    78.45

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    18.86%

  • Return on Assets (ttm)

    13.70%

  • Return on Equity (ttm)

    59.25%

  • Revenue (ttm)

    38.92B

  • Net Income Avi to Common (ttm)

    7.34B

  • Diluted EPS (ttm)

    8.07

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.37B

  • Total Debt/Equity (mrq)

    212.88%

  • Levered Free Cash Flow (ttm)

    -675.32M

Research Analysis: LLY

View More

Company Insights: LLY

Research Reports: LLY

View More

People Also Watch